The influence of PSA autoantibodies in prostate cancer patients: A prospective clinical study-II

Oncotarget

Volumn 8, Issue 11, 2017, Pages 17643-17650

  Nakajima, Kosei ^a   Heilbrun, Lance K ^a,b   Smith, Daryn ^a,b   Hogan, Victor ^a   Raz, Avraham ^a   Heath, Elisabeth ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

False results; Galectin 3; Prostate cancer; PSA autoantibody; PSA test

Indexed keywords

GALECTIN 3; PROSTATE SPECIFIC ANTIGEN; AUTOANTIBODY; AUTOANTIGEN; TUMOR MARKER;

ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; AGED; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; PROSTATE TUMOR;

AGED; AUTOANTIBODIES; AUTOANTIGENS; BIOMARKERS, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 85015195296     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12620     Document Type: Article

References (15)

1. Moyer VA. US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157(2):120-134.
2. Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT and Denmeade SR. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate. 2011; 71(15):1595-1607.
3. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R and Montie JE. Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353(12):1224-1235.
4. Chu TM, Kuriyama M, Johnson E, Papsidero LD, Killian CS, Murphy GP and Wang MC. Circulating antibody to prostate antigen in patients with prostatic cancer. Ann N Y Acad Sci. 1983; 417:383-389.
5. Zisman A, Zisman E, Lindner A, Velikanov S, Siegel YI and Mozes E. Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia. J Urol. 1995; 154(3):1052-1055.
6. Lokant MT and Naz RK. Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis). Andrologia. 2015; 47(3):328-332.
7. Liu FT and Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005; 5(1):29-41.
8. Nakajima K, Kho DH, Yanagawa T, Zimel M, Heath E, Hogan V and Raz A. Galectin-3 in bone tumor microenvironment: A beacon for individual skeletal metastasis management. Cancer Metastasis Rev. 2016; 35(2):333-346.
9. Balan V, Wang Y, Nangia-Makker P, Kho DH, Bajaj M, Smith D, Heilbrun L, Raz A and Heath E. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 2013; 4(4):542-529. doi: 10.18632/oncotarget.923.
10. Nakajima K, Heilbrun L, Hogan V, Smith D, Heath E and Raz A. Positive associations between Galectin-3 and PSA levels in prostate cancer patients: A prospective clinical study-I. Oncotarget. 2016; doi: 10.18632/oncotarget.12619.
11. Nakajima K, Kho DH, Yanagawa T, Harazono Y, Hogan V, Chen W, Ali FR, Mehra R and Raz A. Galectin-3 cleavage alters bone remodeling: Different outcomes in breast and prostate cancer skeletal metastasis. Cancer Res. 2016 76(6):1391-1402.
12. Mathews KP, Konstantinov KN, Kuwabara I, Hill PN, Hsu DK, Zuraw BL and Liu FT. Evidence for IgG autoantibodies to galectin-3, a beta-galactoside-binding lectin (Mac-2, epsilon binding protein, or carbohydrate binding protein 35) in human serum. J Clin Immunol. 1995; 15(6):329-337.
13. GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ and KantoffPW. Humoral immune response against nontargeted tumor antigens after treatment with Sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res. 2015; 21(16):3619-3630.
14. Nakajima K, Kho DH, Yanagawa T, Harazono Y, Gao X, Hogan V and Raz A. Galectin-3 inhibits osteoblast differentiation through notch signaling. Neoplasia. 2014; 16(11):939-949.
15. Hintze J. Power and Sample Size (PASS) 11. NCSS, LLC Kaycville, Utah, USA. 2011; www.ncss.com.